Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karen Robertson

Nurse Practitioner, Adult Health Greenville, SC Nurse Practitioner

NPI 1447225610 CMS profile 65342

203 Mills Ave, Greenville, SC 29605

Open in the dashboard

General payments

$68,925

632 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Robertson of Greenville, SC is reported in the CMS Open Payments database as having received $68,925 across 632 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,901 164
2024 General $9,846 115
2023 General $10,258 139
2022 General $17,502 137
2021 General $14,417 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Robertson
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Karen Robertson were reported at $16,901. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Karen Robertson Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $14,417 $138 $43–$438 $132
2022 $17,502 $165 $54–$494 $149
2023 $10,258 $178 $61–$549 $160
2024 $9,846 $186 $62–$575 $164
2025 $16,901 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Akebia Therapeutics Inc $26,701 122 payments
  2. AstraZeneca Pharmaceuticals LP $12,422 81 payments
  3. Amgen Inc. $12,311 85 payments
  4. Horizon Therapeutics plc $8,432 66 payments
  5. Novartis Pharmaceuticals Corporation $4,734 26 payments
  6. Otsuka America Pharmaceutical, Inc. $1,013 101 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $610 38 payments
  8. Retrophin, Inc. $571 19 payments
  9. Mallinckrodt Hospital Products Inc. $558 20 payments
  10. ANI Pharmaceuticals, Inc. $294 9 payments
  11. Other $1,280 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37,078 56 payments
  2. Food and Beverage $12,826 508 payments
  3. Travel and Lodging $7,858 48 payments
  4. Consulting Fee $5,425 2 payments
  5. Honoraria $5,338 3 payments
  6. Education $401 15 payments
Products named General payments · program years 2021–2025
  1. Vafseo $14,778 63 payments
  2. Auryxia $12,009 62 payments
  3. LOKELMA $11,877 61 payments
  4. KRYSTEXXA Krystexxa $8,432 66 payments
  5. Parsabiv $7,180 16 payments
  6. KRYSTEXXA Inflammation/Rare Disease $4,367 38 payments
  7. Fabhalta $4,073 19 payments
  8. JYNARQUE $970 97 payments
  9. TAVNEOS $613 26 payments
  10. Kerendia $610 38 payments
  11. Other $3,125 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

503

Median for Nurse Practitioner: 389

Drug cost

$43,344

Median for Nurse Practitioner: $21,885

Branded share of claims

6.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 13 $19,116
Farxiga Dapagliflozin Propanediol Brand 21 $16,497
Sevelamer Carbonate Generic 30 $2,889
Midodrine Hcl Generic 14 $758
Mycophenolate Mofetil Generic 15 $709
Torsemide Generic 31 $554
Lisinopril Generic 37 $373
Losartan Potassium Generic 31 $329
Amlodipine Besylate Generic 49 $277
Carvedilol Generic 22 $249

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$775,084

Of which drugs: $729,360

Medicare patients

363

Average age 75

Services billed

39,600

186 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 58%
Arthritis 55%
Ischemic heart disease 48%
Heart failure 42%
Atrial fibrillation 28%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ferric carboxymaltose, 1 mg J1439 Office 26 35,250 $30,932
Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 Office 14 1,420 $8,031

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
$3,861 — —
Fabhalta
$3,749 — —
JYNARQUE
$330 — —
PURIFIED CORTROPHIN GEL
$172 — —
LOKELMA
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

632 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record